AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS
09/06/2026 – AB Science today announced that new analyses from its phase 3 trial in amyotrophic lateral sclerosis (AB10015) have been accepted for poster presentation at the ENCALS annual meeting (June 24-26, 2026, Madrid, Spain)